In relation to cancer, TGF-β exhibits both anti-tumoral and oncogenic properties; however, many agents blocking the TGF-β signaling pathway have demonstrated promising anti-tumor activity in preclinical studies.10 This evidence concerns the gene TGFB1 and neoplasm.